AIT Therapeutics Announces Third Quarter Financial Results Conference Call/Webcast
Call Scheduled for Friday, November 3, 2017 at 10:30 a.m. ET
NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and nine-months ended September 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, November 3.
Conference Call & Webcast
| Friday, November 3rd @ 10:30am Eastern Time |
|
| Domestic: | 888-438-5449 |
| International: | 719-325-2450 |
| Passcode: | 1870535 |
| Webcast: | http://public.viavid.com/index.php?id=126768 |
| Replays available through November 17: |
|
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 1870535 |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989